Companies › Instituto Grifols
1 active drug program in 1 registered trial: 1 Phase 2; Hematology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AT-III concentrate (ATIII-DAF/DI) Antithrombin III (plasma-derived concentrate) | SERPINC1 | Phase 2 | Antithrombin III Deficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00319228 | AT-III concentrate (ATIII-DAF/DI) | Phase 2 | Antithrombin III Deficiency | Hematology | Dec 2011 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.